X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/18/2900513/0/en/Santhera-s-Shareholders-Approve-all-Board-Proposals-at-Today-s-Annual-General-Meeting.html
https://www.globenewswire.com/news-release/2024/06/18/2900100/0/en/Santhera-Secures-up-to-CHF-69-million-in-Royalty-and-Debt-Financing-to-Fund-Operations-to-Cash-Flow-Break-Even.html
https://www.prnewswire.com/news-releases/pfizers-setback-in-duchenne-muscular-dystrophy-treatment-trial-clears-path-for-sarepta-and-many-other-pharma-companies--delveinsight-302173965.html
https://pharmafile.com/news/santhera-announces-early-access-program-by-partner-sperogenix-for-dmd-treatment/
https://www.globenewswire.com/news-release/2024/06/10/2895721/0/en/Santhera-Announces-Launch-of-Early-Access-Program-in-China-for-AGAMREE-by-its-Partner-Sperogenix.html
https://www.globenewswire.com/news-release/2024/05/28/2888677/0/en/Santhera-Publishes-Agenda-for-its-Annual-General-Meeting.html
https://www.globenewswire.com/news-release/2024/05/28/2888671/0/en/Santhera-Publishes-Annual-Report-2023.html
https://www.globenewswire.com/news-release/2024/03/27/2852892/0/en/Santhera-Announces-NDA-for-Vamorolone-in-Duchenne-Muscular-Dystrophy-Accepted-and-Granted-Priority-Review-by-China-s-NMPA.html
https://www.globenewswire.com//news-release/2024/03/14/2845975/0/en/Santhera-s-Partner-Catalyst-Pharmaceuticals-Launches-AGAMREE-Vamorolone-in-the-United-States.html
https://www.globenewswire.com//news-release/2024/02/14/2828764/0/en/Santhera-Announces-Publication-of-Efficacy-Safety-and-Tolerability-Data-with-Vamorolone-AGAMREE-in-Patients-with-Duchenne-Muscular-Dystrophy-in-Neurology.html
Market Place
Share 
